electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
企業コードECOR
会社名electroCore, Inc.
上場日Jun 22, 2018
最高経営責任者「CEO」Goldberger (Daniel S)
従業員数73
証券種類Ordinary Share
決算期末Jun 22
本社所在地200 Forge Way
都市ROCKAWAY
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号07866
電話番号19732900097
ウェブサイトhttps://www.electrocore.com/
企業コードECOR
上場日Jun 22, 2018
最高経営責任者「CEO」Goldberger (Daniel S)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし